Recent Blog Articles
Postpartum anxiety is invisible, but common and treatable
The popularity of microdosing of psychedelics: What does the science say?
Pouring from an empty cup? Three ways to refill emotionally
Is pregnancy safe for everyone?
New pediatric guidelines on obesity in children and teens
Screening tests may save lives — so when is it time to stop?
Natural disasters strike everywhere: Ways to help protect your health
The case of the bad placebo
Do we feel pain more at night?
If you use cannabis, do it safely
Guru P. Sonpavde, MD
Contributor
Guru P. Sonpavde, MD is the director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus is on clinical trials to develop new drugs and combinations to treat urologic cancers, particularly bladder cancer. He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.
Posts by Guru P. Sonpavde, MD
Guru P. Sonpavde, MD
Cancer treatment: Is a clinical trial right for you?
Treatments
